REFERENCES
- Maurer H, Kraemer T, Springer D, Staack R. Chemistry, pharmacology, toxicology and hepatic metabolism of designer drugs of the amphetamine piperazine and pyrrolidinophenone types. Therapeutic Drug Monitoring 2004; 26: 127–131
- http://www.deadiversion.usdoj.gov/drugs_concern/bzp_tmp/bzp_tmp.htm, United States Drug Enforcement Administration. Drugs and Chemicals of Concern (BZP, TFMPP). 2001
- http://www.nzherald.co.nz, Legal party drugs facing ban. New Zealand Herald 18 March 2004
- United States Drug Enforcement Administration. Scheduling Actions 2002. Federal Register 2002; 67: 59161–59162
- http://www.ndp.govt.nz/committees/eacd/bzppaper20045663, New Zealand Expert Advisory Committee on Drugs. Advice to the Minister on benzylpiperazine (BZP). 2004
- Kaplan BJ, Sadock VA. Comprehensive Textbook of Psychiatry7th edn. Lippincott Williams and Wilkins, Philadelphia 2000; 995–1031
- http://www.erowid.org/chemicals/bzp/bzp_article1.shtml, Connelly B. Neuropharmacology of BZP. 2003